LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Ocular Therapeutix Inc

Затворен

СекторЗдравеопазване

7.01 -5.01

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

6.95

Максимум

7.49

Ключови измерители

By Trading Economics

Приходи

-16M

-64M

Продажби

-6.4M

11M

EPS

-0.372

Марж на печалбата

-602.342

Служители

274

EBITDA

-20M

-64M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+138.57% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-147M

1.2B

Предишно отваряне

12.02

Предишно затваряне

7.01

Настроения в новините

By Acuity

50%

50%

209 / 382 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Ocular Therapeutix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2025 г., 23:20 ч. UTC

Печалби

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13.05.2025 г., 23:48 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13.05.2025 г., 23:43 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.05.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13.05.2025 г., 23:24 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

13.05.2025 г., 23:24 ч. UTC

Пазарно говорене
Печалби

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13.05.2025 г., 22:58 ч. UTC

Печалби

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13.05.2025 г., 22:58 ч. UTC

Печалби

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13.05.2025 г., 22:58 ч. UTC

Печалби

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13.05.2025 г., 22:58 ч. UTC

Печалби

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13.05.2025 г., 22:38 ч. UTC

Печалби

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13.05.2025 г., 22:38 ч. UTC

Печалби

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13.05.2025 г., 22:37 ч. UTC

Печалби

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13.05.2025 г., 22:36 ч. UTC

Печалби

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13.05.2025 г., 22:35 ч. UTC

Печалби

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13.05.2025 г., 22:34 ч. UTC

Печалби

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13.05.2025 г., 22:33 ч. UTC

Печалби

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13.05.2025 г., 22:33 ч. UTC

Печалби

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13.05.2025 г., 22:33 ч. UTC

Печалби

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13.05.2025 г., 22:30 ч. UTC

Печалби

Aristocrat Interim Dividend 44 Australian Cents/Share

13.05.2025 г., 22:30 ч. UTC

Печалби

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13.05.2025 г., 22:29 ч. UTC

Печалби

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13.05.2025 г., 22:28 ч. UTC

Печалби

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13.05.2025 г., 21:15 ч. UTC

Печалби

Nu Holdings 1Q Rev $3.2B >NU

13.05.2025 г., 21:03 ч. UTC

Топ новини

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13.05.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.05.2025 г., 20:32 ч. UTC

Печалби

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13.05.2025 г., 20:31 ч. UTC

Печалби

Alcon 1Q Sales $2.45B >ALC.EB

13.05.2025 г., 20:30 ч. UTC

Печалби

Alcon 1Q Rev $2.47B >ALC.EB

13.05.2025 г., 20:30 ч. UTC

Печалби

Alcon 1Q EPS 70c >ALC.EB

Сравнение с други в отрасъла

Ценова промяна

Ocular Therapeutix Inc Прогноза

Ценова цел

By TipRanks

138.57% нагоре

12-месечна прогноза

Среден 17.63 USD  138.57%

Висок 22 USD

Нисък 14 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocular Therapeutix Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

10

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

6.97 / 7.62Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

209 / 382 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.